ENDRA Life Sciences Inc. filings document a Nasdaq-listed medical technology issuer focused on thermoacoustic biomarker imaging and the TAEUS® Liver device for liver fat assessment in steatotic liver disease, MASLD and MASH. Periodic and current reports disclose operating results, clinical-program updates, research and development spending, liquidity, risk factors and common-stock registration matters.
The company’s SEC record also covers material-event reports on private placement financing, at-the-market equity offering arrangements, digital asset treasury disclosures involving HYPE token holdings, supplemental digital-asset risk factors, Nasdaq continued-listing compliance, workforce-related exit costs and strategic-review matters. Proxy materials document director elections, equity incentive plan amendments, auditor matters and other stockholder voting items.
ENDRA Life Sciences Inc. (NDRA) is identified as the issuer in the supplied metadata; the report text identifies ASP Isotopes Inc. as registrant and says Tetra4 Proprietary Limited, a subsidiary of Renergen Limited, completed commissioning and achieved stable production of liquid helium.
ENDRA Life Sciences Inc. (NDRA) reports ASP Isotopes Inc. and LHE LNG Holdings LLC as 10% owners, with securities held by LHE LNG: 66,846 common shares, pre-funded warrants covering 511,541 common shares, and warrants covering 1,156,774 common shares. The pre-funded warrants have a $0.0001 exercise price; the warrants have a $6.57 exercise price. ASP Isotopes controls LHE LNG, and each entity disclaims beneficial ownership except to the extent of its respective pecuniary interest.
ENDRA Life Sciences Inc. is party to a proposed merger with Noble Africa LLC, a direct wholly owned subsidiary of ASP Isotopes Inc. ASP Isotopes and its wholly owned subsidiary LHE LNG Holdings LLC report beneficial ownership of 254,015 NDRA shares (15.1%), comprising 66,846 common shares and 187,169 shares issuable under pre-funded warrants exercisable within 60 days. The percentage is based on 1,499,912 issued and outstanding shares as of October 6, 2026; another 324,372 shares under pre-funded warrants and 1,156,774 shares under common warrants require stockholder approval before exercise.
Subject to satisfaction or waiver of merger conditions, ASP Isotopes is entitled to 58,554,185 Class B shares at the effective time. Following completion, it is expected to own approximately 26.2% of Class A and 100% of Class B, representing approximately 98.9% of combined voting power, assuming full exercise by LHE LNG of both warrant types. LHE LNG intends to exercise pre-funded warrants to purchase 187,169 shares before the special-meeting record date to vote those shares. A side letter requires ENDRA to maintain a segregated cash balance equal to or greater than the approximately $3.8 million purchase price until the earlier of the strategic alternative closing or payment of the Payment Obligation.
ENDRA Life Sciences Inc.’s preliminary prospectus covers 63,148,401 shares of Class A common stock, 58,554,185 shares of Class B common stock, and pre-funded warrants to purchase Class A common stock for the proposed merger; these share counts do not give effect to the proposed reverse split. Subject to stockholder approval and other closing conditions, ENDRA’s merger subsidiary would merge into Noble Africa, which would survive as ENDRA’s wholly owned subsidiary, and ENDRA would be renamed 4K Resources Inc. Before closing, ASP Isotopes will contribute its Renergen equity interest to Noble Africa for 55,500,000 Class B units; Renergen focuses on helium and LNG.
Noble Africa agreed, subject to closing conditions, to sell units and/or pre-funded warrants for approximately $50 million in gross proceeds; net proceeds are expected to fund working capital, Renergen’s Phase 1 and Phase 2, and merger expenses. ASP Isotopes is expected to hold approximately 98.8% of combined voting power after closing, assuming full exercise of pre-funded warrants; ENDRA intends to use controlled-company exemptions for at least some period. Stockholders are asked to approve a board-selected reverse split, intended to bring the share price to at least $4.00 for Nasdaq minimum-bid compliance. Nasdaq listing approval is a closing condition, and completion is anticipated in the fourth quarter of 2026.
ENDRA Life Sciences Inc. (NDRA) amended its merger agreement with ASP Isotopes, Renergen, Noble Africa LLC and Kruger Merger Sub. The proposed merger remains subject to the agreement’s conditions; if completed, Kruger Merger Sub would merge into Noble Africa, which would survive as ENDRA’s wholly owned subsidiary.
The amendment sets the minimum cash closing requirement at $3,800,002.59, less certain agreed-upon expenses to permit ENDRA to engage in investor relations activities, and removes the proposed classified-board and supermajority-vote provisions. It permits a fifth addendum that would increase Renergen’s borrowing capacity from ASPI from $80 million to up to $120 million; a contemplated sixth addendum at or before closing would raise it from $120 million to up to $200 million. Separately, ENDRA and an ASPI subsidiary removed the 4.99% beneficial ownership limit on warrant exercises. A portion of the pre-funded warrants covering 324,372 shares and all common warrant shares become exercisable only after ENDRA stockholder approval.
ENDRA Life Sciences Inc. amended its merger agreement with ASP Isotopes, Noble Africa, Renergen and Kruger Merger Sub. Under the agreement, Kruger Merger Sub would merge with and into Noble Africa, which would survive as ENDRA's wholly owned subsidiary, subject to satisfaction or waiver of the closing conditions.
The revised minimum cash closing condition is $3,800,002.59 less certain agreed-upon expenses. The amendment removes the requirement for a three-class board after closing and replaces the proposed charter form to remove classified-board and specified supermajority-vote provisions. It permits Renergen to enter a fifth ASPI Term Loan Facility addendum that would increase borrowing capacity from $80 million to up to $120 million; a contemplated sixth addendum, to be entered at or before closing, would increase capacity from $120 million to up to $200 million.
ENDRA and LHE LNG Holdings, ASPI's wholly owned subsidiary, also amended the warrants to remove the 4.99% beneficial-ownership exercise limit. The May 27, 2026 agreement provided for up to 511,541 pre-funded warrant shares at $0.0001 per share and up to 1,156,774 common warrant shares at $6.57 per share. A portion covering 324,372 pre-funded warrant shares and all common warrant shares only become exercisable upon stockholder approval.
ENDRA Life Sciences Inc. launched a website on September 24, 2026, at redchip.com/stocks/NDRA in connection with proposed transactions involving ENDRA, ASP Isotopes, Renergen and Noble Africa. ENDRA intends to file a Form S-4 registration statement containing a proxy statement and prospectus; this communication is not a substitute for those materials.
The communication identifies stockholder approval, financing and other conditions as risks to completion. It also cautions that forward-looking statements are not guarantees of future performance.
ENDRA Life Sciences Inc. (NDRA) filed a communication under Form 425 that provides the transcript of a 30-second national television advertisement promoting proposed merger and related transactions among ENDRA, Noble Africa LLC, Renergen Limited and ASP Isotopes, Inc. The ad highlights Noble Africa as owning a prolific helium asset under development for U.S. supply, with funding anchored by the U.S. Development Finance Corporation, and references a recently announced proposed merger with Nasdaq-listed NDRA. Extensive accompanying text consists of forward-looking statement cautions, detailed risk factors related to the Proposed Transactions and Renergen’s operations, and notices about forthcoming Form S-4, Proxy Statement and prospectus materials, emphasizing that this communication is not an offer or solicitation for any securities.
ENDRA Life Sciences Inc. (NDRA) released a presentation transcript describing proposed transactions under which ASP Isotopes plans to list its helium business by combining Noble Africa, the holding company for Renergen, with ENDRA via a reverse merger. ASP Isotopes expects to own about 89% of the listed Noble Africa, with roughly 10%–11% free float, subject to potential additional capital raising. Management highlighted Renergen’s Virginia Gas Project in South Africa, noting that the plant began cooling and commissioning in August, has reached operating temperature of 4 Kelvin, and is expected to begin producing commercial product by the end of September, positioning the business as a pure‑play, revenue‑generating helium company. The transcript also includes extensive cautionary language about forward‑looking statements and directs ENDRA stockholders to review a planned Form S‑4 registration statement and proxy statement for full details of the proposed merger and related risks.
ENDRA Life Sciences Inc. (NDRA) is the issuer of record for this submission, which reproduces a Form 8-K for ASP Isotopes Inc. ASP Isotopes reports that it issued a press release on September 8, 2026 announcing its inaugural Capital Markets Day held in London and made an accompanying investor presentation available.
The press release is furnished as Exhibit 99.1, and the presentation is available on ASP Isotopes’ website under Investor Relations. ASP Isotopes states that the information is furnished under Regulation FD, is not deemed “filed” under the Exchange Act or Securities Act, and includes forward-looking statements subject to risks described in its Annual Report on Form 10-K and other SEC reports.